The pSivida Corp. (PSDV) Earns “Outperform” Rating from FBR & Co

The pSivida Corp. (PSDV) Earns “Outperform” Rating from FBR & Co

pSivida Corp. (PSDV) opened at 2.25 on Monday. pSivida Corp. has a one year low of $1.50 and a one year high of $4.25. The firm has a 50-day moving average of $1.96 and a 200-day moving average of $1.82. The stock’s market capitalization is $88.35 million.

FBR & Co reissued their outperform rating on shares of pSivida Corp. (NASDAQ:PSDV) in a research report sent to investors on Monday, May 15th. FBR & Co currently has a $7.00 price target on the stock.

A number of hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new stake in shares of pSivida Corp. during the fourth quarter valued at approximately $3,898,000. Vanguard Group Inc. boosted its position in pSivida Corp. by 3.5% in the first quarter. Vanguard Group Inc. now owns 1,145,802 shares of the company’s stock worth $1,971,000 after buying an additional 38,897 shares during the last quarter. Renaissance Technologies LLC boosted its position in pSivida Corp. by 6.2% in the first quarter. Renaissance Technologies LLC now owns 963,043 shares of the company’s stock worth $1,656,000 after buying an additional 56,043 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in pSivida Corp. by 0.5% in the first quarter. Geode Capital Management LLC now owns 143,049 shares of the company’s stock worth $246,000 after buying an additional 756 shares during the last quarter. Institutional investors and hedge funds own 29.03% of the company’s stock. About pSivida Corp.

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:PSDV”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment